Case-specific guidance on spc therapy
Case-specific guidance on spc therapy has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Feb 26, 2026: “SOLO study: A single-pill combination strategy in general practice to optimize blood pressure control in a multi-ethnic community”.
1 paper studies it3 findingsUpdated
See all 1 papers on case-specific guidance on spc therapy
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“SPC initiation was higher in the IC than US (25.1% vs. 9.6%, p<0.001).”
None of its findings points the other way.
- 1 lab in 1 country
- Human trial1
Studies in people
1 study gave case-specific guidance on spc therapy to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases blood pressure-15.7/-6.9 mmHg vs. -10.4/-4.6 mmHg up: Increases target blood pressure achievement57.3% vs. 48.1%; OR: 1.4, 95%CI:1.0-2.1 | Trialmedian follow-up of 367 days | 438 peoplemean age 64.5+/-12.2 yearsOlder adults; hypertension | medRxiv, Feb 26, 2026 |
What did studies of case-specific guidance on spc therapy find?
3Studies of case-specific guidance on spc therapy measured 3 outcomes: target blood pressure achievement, blood pressure and single-pill combination therapy.
Target blood pressure achievement
upin humans1OR 1.4
1 study
Target blood pressure achievement
upin humans1OR 1.4
Case-specific guidance on spc therapy increases target blood pressure achievement in humans (hypertension) (57.3% vs. 48.1%; OR: 1.4, 95%CI:1.0-2.1).
“Target BP was more often achieved in the IC (57.3% vs. 48.1%; OR: 1.4, 95%CI:1.0-2.1).”
Human trialhypertensionmedian follow-up of 367 daysn = 438
medRxivPreprint
Blood pressure
downin humans1
1 study
Blood pressure
downin humans1
Case-specific guidance on spc therapy decreases blood pressure in humans (hypertension) (-15.7/-6.9 mmHg vs. -10.4/-4.6 mmHg).
“SBP/DBP decreased by -15.7/-6.9 mmHg in the IC and -10.4/-4.6 mmHg in the UC.”
Human trialhypertensionmedian follow-up of 367 daysn = 438
medRxivPreprint
Single-pill combination therapy
upin humans1
1 study
Single-pill combination therapy
upin humans1
Case-specific guidance on spc therapy increases single-pill combination therapy in humans (hypertension) (25.1% vs. 9.6%, p<0.001).
“SPC initiation was higher in the IC than US (25.1% vs. 9.6%, p<0.001).”
Human trialhypertensionmedian follow-up of 367 daysn = 438
medRxivPreprint